Piramal Pharma has received Board approval to exercise its call option to acquire the remaining 26 percent equity stake in Yapan Bio from its existing shareholders. The proposed transaction would increase Piramal Pharma’s shareholding in Yapan from 74 percent to 100 percent, making it a wholly owned subsidiary of the company.
Following the approval, Piramal Pharma has initiated discussions with Yapan’s existing shareholders on matters related to the completion of the proposed acquisition. The final terms, including the acquisition consideration and effective date of share transfer, are yet to be finalised.
The company stated that it will make the required disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with the applicable SEBI Master Circular dated January 30, 2026, after the execution of definitive agreements and completion of the transaction.
Yapan Bio is a Contract Development and Manufacturing Organisation (CDMO) specialising in process development, characterisation and Phase 1/2 Good Manufacturing Practice (GMP) manufacturing services for vaccines and biologics.
Upon completion of the proposed transaction, Yapan Bio will become a wholly owned subsidiary of Piramal Pharma.
Last news about this category
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy